论文部分内容阅读
近日,耶鲁大学癌症中心研究人员利用一种新的分子分析工具RNAScope,准确地检测出针对早期乳腺癌的免疫治疗的一个重要靶标的水平。诊断测试使用RNAScope,测量福尔马林固定的癌组织中PD-L1(细胞程序性死亡配体PD L1)mRNA的量。RNAscope是一种新型RNA原位杂交技术,基于其独特的探针设计与背景抑制技术,并且融合传统RNA原位杂交技术与FISH技术的优点,使单个RNA的转录变得可视化,是目前最精准的RNA检测技术。PD-L1是目前几种新型免疫刺激疗法的靶标。这项研究结果发表在Clinical Cancer Research杂志上。
Recently, researchers at Yale University Cancer Center used a new molecular analysis tool, RNAScope, to accurately detect the level of an important target for immunotherapy of early-stage breast cancer. Diagnostic test The amount of PD-L1 (apoptosis ligand PD L1) mRNA in formalin-fixed cancerous tissue was measured using RNAScope. RNAscope is a new RNA in situ hybridization technology that is based on its unique probe design and background suppression technology and combines the advantages of traditional RNA in situ hybridization with FISH technology to visualize the transcription of individual RNAs and is by far the most accurate RNA detection technology. PD-L1 is the target of several new immunostimulatory therapies. The findings are published in the journal Clinical Cancer Research.